Ampio Pharmaceuticals (AMPE)

Overall impact
C (55)

Commentary

Ampio Pharmaceuticals is an average overall performer. With a 'C' rating of 54.8 for overall impact (51st percentile compared to all companies), Ampio Pharmaceuticals ranks 485th out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 481 others, and ahead of Grifols, Jazz Pharmaceuticals, Citius Pharmaceuticals and 97 others. On top material causes for Ampio Pharmaceuticals's industry (Pharmaceuticals & Biotech), Ampio Pharmaceuticals performs well in Technology Innovation (89.6 score) and Disease Eradication (96.4) and performs poorly in Decent, Safe Work Opportunities (17.8 score), Equal Pay and Opportunity (25.3), Reduced Waste (33.8) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause AMPE
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1996
Employees
6
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Co, United States
Share classes
AMPE
Description
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.
Material causes
Ethos considers the following causes material for Ampio Pharmaceuticals, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.